Poll

Poll: Is DRE still a relevant tool in the management of prostate cancer?

Do you feel that DRE is still a relevant tool in the management of prostate cancer? Take our latest poll and let us know.

Yes
No
Not sure

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
2 experts in this video
Transitioning to Oral ADT and Drug-Drug Interactions
Timothy McClure, MD, highlights data on IRE for prostate tissue ablation
Timothy McClure, MD, highlights data on IRE for prostate tissue ablation
Advances across urology: Insights from UNC faculty
Advances across urology: Insights from UNC faculty
Related Content
Novel alpha particle therapy holds promise in prostate, bladder cancer
August 21st 2025

Novel alpha particle therapy holds promise in prostate, bladder cancer

Robert B. Den, MD
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
August 21st 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
3d rendered medically accurate illustration of prostate cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
August 21st 2025

PSMA PET/CT prior to salvage radiotherapy may improve overall survival

Hannah Clarke
Dr. Murphy on increasing diversity in cancer clinical trials
August 21st 2025

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
FDA grants de novo authorization to ArteraAI Prostate
August 21st 2025

FDA grants de novo authorization to ArteraAI Prostate

Hannah Clarke Benjamin P. Saylor
Study offers insights into optimal patient selection for HIFU in prostate cancer
August 21st 2025

Study offers insights into optimal patient selection for HIFU in prostate cancer

Hannah Clarke
© 2025 MJH Life Sciences

All rights reserved.